5Yoshinori ho, Yohei Osaki, Nahomi Tokudome, et al. Efficacy of S -1 in heavily pretreated patients with metastatic breast cancer: cross- resistance to capecitabine [ J]. Breast Cancer,2009,2:126 -131.
6OShaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline - pretreated patients with advanced breast cancer: Phase Ⅲ trial re- sults[ J]. J Clin Oncol,2002,20(12) :2812.
7Figgit DP, Wiseman LR. Docetaxel: an update of its use in ad- vanced breast cancer[ J]. Drugs ,2000,59:621 - 651.
8Sparano JA. Taxanes for breast cancer : an evidence - based review of randomized phase Ⅱ and phase Ⅲ trials [ J ]. Clin Bresat Cancer, 2000,1:30 -40.
9Miwa M, Ura M, Nishida M, et al. Design of anoveloraltlu or opyri- midine carhamate, eapeeitabine, which generates 5 fluorouraeil se- lectively in tumors by enzymes concentrated in human liver and eancer tissue [ J ]. Eur J Cancer, 1998,34 ( 8 ) : 1274 - 1281.
10John Crown, Veronique Dieras, Manfred Kaufmann, et al. Chemo- therapy for metastatic breast cancer report of a European expert panel[ J]. Lancet Oncol,2002,3 ( 12 ) :719.
